AC  GenProp2092
DE  GLP-1 signalled increase in cAMP
TP  SYSTEM
AU  Rawlings ND
TH  1
RN  [1]
RM  17306374
RT  Mechanisms of action of glucagon-like peptide 1 in 
RT  the pancreas. 
RA  Doyle ME; Egan JM; 
RL  Pharmacol Ther 2007;113:546-593.
RN  [2]
RM  8405712
RT  Cloning and functional expression of the human islet 
RT  GLP-1 receptor. Demonstration that exendin-4 is an 
RT  agonist and exendin-(9-39) an antagonist of the 
RT  receptor. 
RA  Thorens B; Porret A; BÃ¼hler L; Deng SP; Morel P; 
RA  Widmann C; 
RL  Diabetes 1993;42:1678-1682.
RN  [3]
RM  19817800
RT  Roles of cAMP signalling in insulin granule exocytosis. 
RA  Seino S; Takahashi H; Fujimoto W; Shibasaki T; 
RL  Diabetes Obes Metab 2009;11 Suppl 4:180-188.
DC  Insulin secretion
DR  KEGG; map04911;
CC  Insulin is secreted by the pancreatic beta cells. Its
CC  secretion can be stimulated by the import of glucose
CC  via a surface transporter, and metabolism of glucose
CC  increases intracellular ATP, inhibiting ATP-sensitive
CC  potassium channels, causing an influx of calcium into
CC  the cell.  Alternatively, there are surface receptors
CC  for peptide hormones such as glucogon-like peptide 1.  
CC  Binding triggers adenylyl cyclase activation, an 
CC  increase in cAMP, activation of cAMP-dependent second
CC  messengers such as protein kinase A, and secretion of
CC  insulin from vesicles [1-3]. This property describes
CC  the steps of the pathway leading to an increase in 
CC  cAMP.
**  This Genome Property models the release of insulin
**  stored in vesicles induced by peptide hormone GLP-1.
**  It is difficult to model the pathway initiated by
**  glucose, because it involves the TCA cycle and
**  it is the increase in ATP that triggers Na+/K+ flux
**  and an increase in intracellular Ca2+. 
**  Part of the pathway induced by peptide hormones 
**  requires de novo synthesis of insulin, so is also
**  difficult to model.
**  Does it make sense to use glucagon model for GLP1? - yes (LR)
**  SN1 IPR015550 in 1 other prop
--
SN  1
ID  Glucagon-like peptide-1
DN  Glucagon (GLP-1)
RQ  1
EV  IPR015550; PR00277; sufficient;
TG  GO:0005179;
--
SN  2
ID  Glucagon-like peptide 1 receptor
DN  GPCR, family 2, glucagon-like peptide-1 receptor (GLP-1R)
RQ  1
EV  IPR003292; PR01355; sufficient;
EV  IPR003292; PTHR12011:SF245; sufficient;
EV  IPR003292; cd15268; sufficient;
TG  GO:0044508;
--
SN  3
ID  Guanine nucleotide-binding protein G subunit alpha
DN  Guanine nucleotide binding protein (G-protein), alpha subunit (GNA)
RQ  1
EV  IPR001019; PF00503; sufficient;
EV  IPR001019; PR00318; sufficient;
EV  IPR001019; PTHR10218; sufficient;
EV  IPR001019; SM00275; sufficient;
EV  IPR001019; cd00066; sufficient;
TG  GO:0019001;
--
SN  4
ID  Guanine nucleotide-binding protein G subunit beta
DN  Guanine nucleotide-binding protein G subunit beta (GNB)
RQ  1
EV  IPR016346; PTHR19850; sufficient;
TG  GO:0003924;
--
SN  5
ID  Guanine nucleotide-binding protein G subunit gamma
DN  Guanine nucleotide-binding protein G subunit gamma (GNG)
RQ  1
EV  IPR001770; PTHR13809; sufficient;
EV  IPR001770; PR00321; sufficient;
TG  GO:0003924;
--
SN  6
ID  Adenylate cyclase
DN  Adenylate cyclase (AC)
RQ  1
EV  IPR030672; PIRSF039050; sufficient;
TG  GO:0004016;
//
